REG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc
14/08/2025 15:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250814:nRSN3859Va&default-theme=true
RNS Number : 3859V Citadel Group 14 August 2025
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
1. KEY INFORMATION
(a) Full name of discloser Citadel Group
(b) Owner or controller of interests and short positions disclosed, if N/A
different from 1(a)
The naming of nominee or vehicle companies is insufficient. For a trust, the
trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this MURAL ONCOLOGY PLC
form relates
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree, state N/A
this and specify identity of offeror/offeree (Note 1)
(e) Date position held/dealing undertaken 13 August 2025
For an opening position disclosure, state the latest practicable date prior to
the disclosure
(f) In addition to the company in 1(c) above, is the discloser also N/A
making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class
of relevant securities of the offeror or offeree named in 1(c), copy table 2
for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or
offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security Common Stock ISIN IE000LK2BOB4
(Note 3)
$0.01 ordinary shares
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled 238,805 1.37 0 0.00
(2) Cash-settled derivatives 0 0.00 23 0.00
(3) Stock-settled derivatives (including options) and agreements to 27,800 0.16 152,800 0.88
purchase/ sell
Total 266,605 1.53 152,823 0.88
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any
open stock-settled derivative positions (including traded options), or
agreements to purchase or sell relevant securities, should be given on a
Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE
DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security
securities (Note 5)
Common Buy Transaction 7,980 1.7000 USD
Common Buy Transaction 5,580 1.7001 USD
Common Buy Transaction 8 1.7012 USD
Common Buy Transaction 10,648 1.7028 USD
Common Buy Transaction 2,775 1.7087 USD
Common Buy Transaction 213 1.7100 USD
Common Buy Transaction 4,792 1.7200 USD
Common Buy Transaction 59 1.7300 USD
Common Buy Transaction 13,567 1.7329 USD
Common Buy Transaction 6,277 1.7360 USD
Common Buy Transaction 8,196 1.7400 USD
Common Buy Transaction 325 1.7401 USD
Common Buy Transaction 4,676 1.7401 USD
Common Buy Transaction 450 1.7408 USD
Common Buy Transaction 2,300 1.7436 USD
Common Buy Transaction 100 1.7490 USD
Common Buy Transaction 171 1.7500 USD
Common Buy Transaction 2,100 1.7514 USD
Common Buy Transaction 2,000 1.7520 USD
Common Buy Transaction 400 1.7542 USD
Common Buy Transaction 499 1.7560 USD
Common Buy Transaction 578 1.7600 USD
Common Buy Transaction 2 1.7609 USD
Common Buy Transaction 2,740 1.7687 USD
Common Buy Transaction 3 1.7800 USD
Common Buy Transaction 100 1.7819 USD
Common Buy Transaction 10,667 1.7896 USD
Common Buy Transaction 1 1.7950 USD
Common Sell Transaction 5,717 1.7000 USD
Common Sell Transaction 300 1.7094 USD
Common Sell Transaction 400 1.7099 USD
Common Sell Transaction 3,100 1.7159 USD
Common Sell Transaction 1,888 1.7184 USD
Common Sell Transaction 500 1.7189 USD
Common Sell Transaction 700 1.7200 USD
Common Sell Transaction 1,400 1.7240 USD
Common Sell Transaction 59 1.7300 USD
Common Sell Transaction 8,196 1.7400 USD
Common Sell Transaction 17,361 1.7481 USD
Common Sell Transaction 200 1.7490 USD
Common Sell Transaction 765 1.7500 USD
Common Sell Transaction 90 1.7564 USD
Common Sell Transaction 5 1.7600 USD
Common Sell Transaction 24 1.7900 USD
Common Sell Transaction 201 1.7979 USD
Ap29
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price
relevant description e.g. opening/ closing a long/ short position, increasing/ reducing a long/ reference per unit
security e.g. CFD short position securities (Note 5)
(Note 6)
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, purchasing, selling, varying Number Exercise Type Expiry Option
relevant description e.g. call etc. of
price per e.g. date money
security option securities unit American,
paid/
to which European received per unit
option
etc.
relates
(Note 6)
Common Call Option Sell Transaction 1,500 5.0000 USD American 2027-01-15 0.0100 USD
Common Call Option Sell Transaction 8,600 5.0000 USD American 2027-01-15 0.0200 USD
Common Call Option Sell Transaction 1,700 5.0000 USD American 2027-01-15 0.0300 USD
Common Call Option Sell Transaction 3,000 5.0000 USD American 2027-01-15 0.0400 USD
Common Call Option Sell Transaction 3,900 5.0000 USD American 2027-01-15 0.0500 USD
Common Call Option Sell Transaction 11,200 2.5000 USD American 2027-01-15 0.1400 USD
(ii) Exercise
Class of Product Exercising/ Number of Exercise
relevant description exercised securities price per
security e.g. call against unit
option (Note 5)
(d) Other dealings (including transactions in respect of
new securities) (Note 3)
Class of Nature of dealing Details Price per unit (if
relevant e.g. subscription, applicable)
security conversion, exercise (Note 5)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the person
making the disclosure and any party to the offer or any person acting in
concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to
options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.
None
(c) Attachments
Is a Supplemental Form 8 attached? YES
Date of disclosure 14 August 2025
Contact name Paula Santos
Telephone number 020 7645 9700
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory
Information Service.
Ap32
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person making Citadel Group
disclosure:
Name of offeror/offeree in relation MURAL ONCOLOGY PLC
to whose relevant securities the
disclosure relates:
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of Product Written or Number of Exercise Type Expiry
relevant description purchased securities to price e.g. date
security e.g. call
which option per unit American,
option
or derivative European
relates etc.
Common Call Option Purchased 400 2.5 USD American 15/08/2025
Common Put Option Purchased -200 7.5 USD American 15/08/2025
Common Put Option Purchased -7,200 2.5 USD American 19/09/2025
Common Call Option Purchased 800 5.0 USD American 19/12/2025
Common Call Option Purchased 9,000 2.5 USD American 20/03/2026
Common Put Option Purchased -200 5.0 USD American 19/09/2025
Common Call Option Purchased 14,600 5.0 USD American 19/09/2025
Common Call Option Purchased 2,000 7.5 USD American 20/03/2026
Common Call Option Purchased 1,000 5.0 USD American 20/03/2026
Common Put Option Purchased -4,800 2.5 USD American 15/08/2025
Common Put Option Purchased -80,700 2.5 USD American 15/01/2027
Common Put Option Purchased -200 5.0 USD American 15/08/2025
Common Put Option Purchased -3,100 2.5 USD American 19/12/2025
Common Call Option Sold -200 7.5 USD American 19/09/2025
Common Call Option Sold -33,100 5.0 USD American 15/01/2027
Common Call Option Sold -5,000 2.5 USD American 19/12/2025
Common Call Option Sold -17,200 2.5 USD American 19/09/2025
Common Call Option Sold -900 2.5 USD American 15/01/2027
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest or position
can be fully understood:
Ap33
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING
DIRECTORS' AND OTHER EMPLOYEE OPTIONS)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
It is not necessary to provide details on a Supplemental Form with regard to
cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in
doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act,
1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPPKQBKDBKDKFDRecent news on Mural Oncology
See all newsREG-Millennium Partners, L.P. Form 8.3 - Mural Oncology plc
AnnouncementREG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc
AnnouncementREG-The Vanguard Group, Inc. Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
AnnouncementREG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc
AnnouncementREG - BlackRock Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc
Announcement